{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:32:52Z","timestamp":1788813172117,"version":"build-2803163510"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["098330\/Z\/12\/Z"],"award-info":[{"award-number":["098330\/Z\/12\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UCL ARUK network"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13195-019-0477-0","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T11:03:18Z","timestamp":1553252598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"11","author":[{"name":"LonDownS Consortium","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9261-9924","authenticated-orcid":false,"given":"Carla M.","family":"Startin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hamburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalyn","family":"Hithersay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances K.","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kin Y.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Lle\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lovestone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilla","family":"Parnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Hye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Strydom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,21]]},"reference":[{"key":"477_CR1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrn3983","volume":"16","author":"FK Wiseman","year":"2015","unstructured":"Wiseman FK, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz VL, Fisher EM, Strydom A. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci. 2015;16:564\u201374.","journal-title":"Nat Rev Neurosci"},{"key":"477_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/jir.12074","volume":"58","author":"M McCarron","year":"2014","unstructured":"McCarron M, McCallion P, Reilly E, Mulryan N. A prospective 14-year longitudinal follow-up of dementia in persons with Down syndrome. J Intellect Disabil Res. 2014;58:61\u201370.","journal-title":"J Intellect Disabil Res"},{"key":"477_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3233\/JAD-170624","volume":"61","author":"A Sinai","year":"2018","unstructured":"Sinai A, Mokrysz C, Bernal J, Bohnen I, Bonell S, Courtenay K, Dodd K, Gazizova D, Hassiotis A, Hillier R, et al. Predictors of age of diagnosis and survival of Alzheimer\u2019s disease in Down syndrome. J Alzheimers Dis. 2018;61:717\u201328.","journal-title":"J Alzheimers Dis"},{"key":"477_CR4","doi-asserted-by":"crossref","unstructured":"Hithersay R, Startin CM, Hamburg S, Mok KY, Hardy J, Fisher EMC, Tybulewicz VLJ, Nizetic D, Strydom A. Association of dementia with mortality among adults with Down syndrome older than 35 years. JAMA Neurol. 2019;76:152\u201360.","DOI":"10.1001\/jamaneurol.2018.3616"},{"key":"477_CR5","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/ejhg.2012.294","volume":"21","author":"J Wu","year":"2013","unstructured":"Wu J, Morris JK. The population prevalence of Down\u2019s syndrome in England and Wales in 2011. Eur J Hum Genet. 2013;21:1016\u20139.","journal-title":"Eur J Hum Genet"},{"key":"477_CR6","doi-asserted-by":"crossref","unstructured":"Mann DMA, Davidson YS, Robinson AC, Allen N, Hashimoto T, Richardson A, Jones M, Snowden JS, Pendleton N, Potier MC, et al. Patterns and severity of vascular amyloid in Alzheimer\u2019s disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer\u2019s disease. Acta Neuropathol. 2018;136:569\u201387.","DOI":"10.1007\/s00401-018-1866-3"},{"key":"477_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1365-2559.1988.tb02018.x","volume":"13","author":"DM Mann","year":"1988","unstructured":"Mann DM. Alzheimer\u2019s disease and Down\u2019s syndrome. Histopathology. 1988;13:125\u201337.","journal-title":"Histopathology."},{"key":"477_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.freeradbiomed.2017.08.024","volume":"114","author":"P Zis","year":"2018","unstructured":"Zis P, Strydom A. Clinical aspects and biomarkers of Alzheimer\u2019s disease in Down syndrome. Free Radic Biol Med. 2018;114:3\u20139.","journal-title":"Free Radic Biol Med"},{"key":"477_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3233\/JAD-160836","volume":"56","author":"E Doran","year":"2017","unstructured":"Doran E, Keator D, Head E, Phelan MJ, Kim R, Totoiu M, Barrio JR, Small GW, Potkin SG, Lott IT. Down syndrome, partial trisomy 21, and absence of Alzheimer\u2019s disease: the role of APP. J Alzheimers Dis. 2017;56:459\u201370.","journal-title":"J Alzheimers Dis"},{"key":"477_CR10","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/ana.410430316","volume":"43","author":"VP Prasher","year":"1998","unstructured":"Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, Butler AC. Molecular mapping of Alzheimer-type dementia in Down\u2019s syndrome. Ann Neurol. 1998;43:380\u20133.","journal-title":"Ann Neurol"},{"key":"477_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","volume":"12","author":"J Hardy","year":"1991","unstructured":"Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol Sci. 1991;12:383\u20138.","journal-title":"Trends Pharmacol Sci"},{"key":"477_CR12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","volume":"6","author":"DJ Selkoe","year":"1991","unstructured":"Selkoe DJ. The molecular pathology of Alzheimer\u2019s disease. Neuron. 1991;6:487\u201398.","journal-title":"Neuron."},{"key":"477_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1365-2788.2006.00902.x","volume":"51","author":"ML Margallo-Lana","year":"2007","unstructured":"Margallo-Lana ML, Moore PB, Kay DW, Perry RH, Reid BE, Berney TP, Tyrer SP. Fifteen-year follow-up of 92 hospitalized adults with Down\u2019s syndrome: incidence of cognitive decline, its relationship to age and neuropathology. J Intellect Disabil Res. 2007;51:463\u201377.","journal-title":"J Intellect Disabil Res"},{"key":"477_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, Mormino E, Chhatwal J, Amariglio R, Papp K, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79:110\u20139.","journal-title":"Ann Neurol"},{"key":"477_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K. Alzheimer\u2019s disease neuroimaging I. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74:557\u201366.","journal-title":"JAMA Neurol"},{"key":"477_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13195-018-0367-x","volume":"10","author":"A Strydom","year":"2018","unstructured":"Strydom A, Heslegrave A, Startin CM, Mok KY, Hardy J, Groet J, Nizetic D, Zetterberg H, Consortium L. Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. Alzheimers Res Ther. 2018;10:39.","journal-title":"Alzheimers Res Ther"},{"key":"477_CR17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1474-4422(18)30285-0","volume":"17","author":"J Fortea","year":"2018","unstructured":"Fortea J, Carmona-Iragui M, Benejam B, Fernandez S, Videla L, Barroeta I, Alcolea D, Pegueroles J, Munoz L, Belbin O, et al. Plasma and CSF biomarkers for the diagnosis of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 2018;17:860\u20139.","journal-title":"Lancet Neurol"},{"key":"477_CR18","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1212\/WNL.0b013e3181b6bb95","volume":"73","author":"C Holmes","year":"2009","unstructured":"Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009;73:768\u201374.","journal-title":"Neurology."},{"key":"477_CR19","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1136\/jnnp.74.6.788","volume":"74","author":"C Holmes","year":"2003","unstructured":"Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D, Perry VH. Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2003;74:788\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"477_CR20","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.biopsych.2010.06.012","volume":"68","author":"W Swardfager","year":"2010","unstructured":"Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer\u2019s disease. Biol Psychiatry. 2010;68:930\u201341.","journal-title":"Biol Psychiatry"},{"key":"477_CR21","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/archneur.61.5.668","volume":"61","author":"MJ Engelhart","year":"2004","unstructured":"Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Hofman A, Witteman JC, Breteler MM. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol. 2004;61:668\u201372.","journal-title":"Arch Neurol"},{"key":"477_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000474940","volume":"17","author":"L D'Anna","year":"2017","unstructured":"D'Anna L, Abu-Rumeileh S, Fabris M, Pistis C, Baldi A, Sanvilli N, Curcio F, Gigli GL, D'Anna S, Valente M. Serum interleukin-10 levels correlate with cerebrospinal fluid amyloid beta deposition in Alzheimer disease patients. Neurodegener Dis. 2017;17:227\u201334.","journal-title":"Neurodegener Dis"},{"key":"477_CR23","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/ng.440","volume":"41","author":"D Harold","year":"2009","unstructured":"Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer\u2019s disease. Nat Genet. 2009;41:1088\u201393.","journal-title":"Nat Genet"},{"key":"477_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/ng.803","volume":"43","author":"P Hollingworth","year":"2011","unstructured":"Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, et al. Common variants at ABCA7, MS4A6A\/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer\u2019s disease. Nat Genet. 2011;43:429\u201335.","journal-title":"Nat Genet"},{"key":"477_CR25","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/ng.2802","volume":"45","author":"JC Lambert","year":"2013","unstructured":"Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat Genet. 2013;45:1452\u20138.","journal-title":"Nat Genet"},{"key":"477_CR26","doi-asserted-by":"publisher","first-page":"e13950","DOI":"10.1371\/journal.pone.0013950","volume":"5","author":"L Jones","year":"2010","unstructured":"Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer\u2019s disease. PLoS One. 2010;5:e13950.","journal-title":"PLoS One"},{"key":"477_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/WAD.0b013e3181aba63a","volume":"24","author":"E Conti","year":"2010","unstructured":"Conti E, Galimberti G, Piazza F, Raggi ME, Ferrarese C. Increased soluble APPalpha, Abeta 1-42, and anti-Abeta 1-42 antibodies in plasma from Down syndrome patients. Alzheimer Dis Assoc Disord. 2010;24:96\u2013100.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"477_CR28","first-page":"316","volume":"8","author":"NC Lee","year":"2016","unstructured":"Lee NC, Yang SY, Chieh JJ, Huang PT, Chang LM, Chiu YN, Huang AC, Chien YH, Hwu WL, Chiu MJ. Blood beta-amyloid and tau in Down syndrome: a comparison with Alzheimer\u2019s disease. Front Aging Neurosci. 2016;8:316.","journal-title":"Front Aging Neurosci"},{"key":"477_CR29","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3233\/JAD-2010-101335","volume":"23","author":"E Head","year":"2011","unstructured":"Head E, Doran E, Nistor M, Hill M, Schmitt FA, Haier RJ, Lott IT. Plasma amyloid-beta as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimers Dis. 2011;23:399\u2013409.","journal-title":"J Alzheimers Dis"},{"key":"477_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jns.2006.12.010","volume":"254","author":"PD Mehta","year":"2007","unstructured":"Mehta PD, Capone G, Jewell A, Freedland RL. Increased amyloid beta protein levels in children and adolescents with Down syndrome. J Neurol Sci. 2007;254:22\u20137.","journal-title":"J Neurol Sci"},{"key":"477_CR31","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jalz.2016.05.001","volume":"12","author":"MF Iulita","year":"2016","unstructured":"Iulita MF, Ower A, Barone C, Pentz R, Gubert P, Romano C, Cantarella RA, Elia F, Buono S, Recupero M, et al. An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: relation to cognitive decline and longitudinal evaluation. Alzheimers Dement. 2016;12:1132\u201348.","journal-title":"Alzheimers Dement"},{"key":"477_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0304-3940(01)01657-3","volume":"301","author":"N Schupf","year":"2001","unstructured":"Schupf N, Patel B, Silverman W, Zigman WB, Zhong N, Tycko B, Mehta PD, Mayeux R. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett. 2001;301:199\u2013203.","journal-title":"Neurosci Lett"},{"key":"477_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0304-3940(97)00966-X","volume":"241","author":"PD Mehta","year":"1998","unstructured":"Mehta PD, Dalton AJ, Mehta SP, Kim KS, Sersen EA, Wisniewski HM. Increased plasma amyloid beta protein 1-42 levels in Down syndrome. Neurosci Lett. 1998;241:13\u20136.","journal-title":"Neurosci Lett"},{"key":"477_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0304-3940(03)00275-1","volume":"342","author":"PD Mehta","year":"2003","unstructured":"Mehta PD, Mehta SP, Fedor B, Patrick BA, Emmerling M, Dalton AJ. Plasma amyloid beta protein 1-42 levels are increased in old Down syndrome but not in young Down syndrome. Neurosci Lett. 2003;342:155\u20138.","journal-title":"Neurosci Lett"},{"key":"477_CR35","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/1096-8628(20001127)95:3<224::AID-AJMG7>3.0.CO;2-B","volume":"95","author":"S Cavani","year":"2000","unstructured":"Cavani S, Tamaoka A, Moretti A, Marinelli L, Angelini G, Di Stefano S, Piombo G, Cazzulo V, Matsuno S, Shoji S, et al. Plasma levels of amyloid beta 40 and 42 are independent from ApoE genotype and mental retardation in Down syndrome. Am J Med Genet. 2000;95:224\u20138.","journal-title":"Am J Med Genet"},{"key":"477_CR36","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/1531-8249(199904)45:4<537::AID-ANA20>3.0.CO;2-2","volume":"45","author":"E Matsubara","year":"1999","unstructured":"Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, Harigaya Y, Okamoto K, Shoji M. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer\u2019s disease and Down\u2019s syndrome. Ann Neurol. 1999;45:537\u201341.","journal-title":"Ann Neurol"},{"key":"477_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/ana.410410220","volume":"41","author":"T Tokuda","year":"1997","unstructured":"Tokuda T, Fukushima T, Ikeda S, Sekijima Y, Shoji S, Yanagisawa N, Tamaoka A. Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down\u2019s syndrome. Ann Neurol. 1997;41:271\u20133.","journal-title":"Ann Neurol"},{"key":"477_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188802","volume":"12","author":"T Kasai","year":"2017","unstructured":"Kasai T, Tatebe H, Kondo M, Ishii R, Ohmichi T, Yeung WTE, Morimoto M, Chiyonobu T, Terada N, Allsop D, et al. Increased levels of plasma total tau in adult Down syndrome. PLoS One. 2017;12:e0188802.","journal-title":"PLoS One"},{"key":"477_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2249.2009.03890.x","volume":"156","author":"MA Kusters","year":"2009","unstructured":"Kusters MA, Verstegen RH, Gemen EF, de Vries E. Intrinsic defect of the immune system in children with Down syndrome: a review. Clin Exp Immunol. 2009;156:189\u201393.","journal-title":"Clin Exp Immunol"},{"key":"477_CR40","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1136\/adc.2003.046219","volume":"89","author":"MJ Goldacre","year":"2004","unstructured":"Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D. Cancers and immune related diseases associated with Down\u2019s syndrome: a record linkage study. Arch Dis Child. 2004;89:1014\u20137.","journal-title":"Arch Dis Child"},{"key":"477_CR41","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1742-2094-10-84","volume":"10","author":"DM Wilcock","year":"2013","unstructured":"Wilcock DM, Griffin WS. Down\u2019s syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J Neuroinflammation. 2013;10:84.","journal-title":"J Neuroinflammation"},{"key":"477_CR42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1744-313X.2010.00914.x","volume":"37","author":"S Cetiner","year":"2010","unstructured":"Cetiner S, Demirhan O, Inal TC, Tastemir D, Sertdemir Y. Analysis of peripheral blood T-cell subsets, natural killer cells and serum levels of cytokines in children with Down syndrome. Int J Immunogenet. 2010;37:233\u20137.","journal-title":"Int J Immunogenet"},{"key":"477_CR43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jped.2016.04.012","volume":"93","author":"ME Zaki","year":"2017","unstructured":"Zaki ME, El-Bassyouni HT, Tosson AM, Youness E, Hussein J. Coenzyme Q10 and pro-inflammatory markers in children with Down syndrome: clinical and biochemical aspects. J Pediatr. 2017;93:100\u20134.","journal-title":"J Pediatr"},{"key":"477_CR44","first-page":"773","volume":"27","author":"MM Corsi","year":"2006","unstructured":"Corsi MM, Dogliotti G, Pedroni F, Palazzi E, Magni P, Chiappelli M, Licastro F. Plasma nerve growth factor (NGF) and inflammatory cytokines (IL-6 and MCP-1) in young and adult subjects with Down syndrome: an interesting pathway. Neuro Endocrinol Lett. 2006;27:773\u20138.","journal-title":"Neuro Endocrinol Lett"},{"key":"477_CR45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1684\/ecn.2012.0307","volume":"23","author":"M Nateghi Rostami","year":"2012","unstructured":"Nateghi Rostami M, Douraghi M, Miramin Mohammadi A, Nikmanesh B. Altered serum pro-inflammatory cytokines in children with Down\u2019s syndrome. Eur Cytokine Netw. 2012;23:64\u20137.","journal-title":"Eur Cytokine Netw"},{"key":"477_CR46","doi-asserted-by":"crossref","first-page":"84489","DOI":"10.18632\/oncotarget.21060","volume":"8","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Che M, Yuan J, Yu Y, Cao C, Qin XY, Cheng Y. Aberrations in circulating inflammatory cytokine levels in patients with Down syndrome: a meta-analysis. Oncotarget. 2017;8:84489\u201396.","journal-title":"Oncotarget."},{"key":"477_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.12688\/wellcomeopenres.9961.1","volume":"1","author":"CM Startin","year":"2016","unstructured":"Startin CM, Hamburg S, Hithersay R, Davies A, Rodger E, Aggarwal N, Al-Janabi T, Strydom A. The LonDownS adult cognitive assessment to study cognitive abilities and decline in Down syndrome. Wellcome Open Res. 2016;1:11.","journal-title":"Wellcome Open Res"},{"key":"477_CR48","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3389\/fnagi.2018.00409","volume":"10","author":"S Westwood","year":"2018","unstructured":"Westwood S, Baird AL, Hye A, Ashton NJ, Nevado-Holgado AJ, Anand SN, Liu B, Newby D, Bazenet C, Kiddle SJ, et al. Plasma protein biomarkers for the prediction of CSF amyloid and tau and [(18)F]-flutemetamol PET scan result. Front Aging Neurosci. 2018;10:409.","journal-title":"Front Aging Neurosci"},{"key":"477_CR49","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s disease. Neurology. 1984;34:939\u201344.","journal-title":"Neurology."},{"key":"477_CR50","doi-asserted-by":"publisher","first-page":"40263","DOI":"10.1038\/srep40263","volume":"7","author":"NK Majbour","year":"2017","unstructured":"Majbour NK, Chiasserini D, Vaikath NN, Eusebi P, Tokuda T, van de Berg W, Parnetti L, Calabresi P, El-Agnaf OM. Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer\u2019s disease. Sci Rep. 2017;7:40263.","journal-title":"Sci Rep"},{"key":"477_CR51","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1212\/WNL.0000000000001859","volume":"85","author":"D Alcolea","year":"2015","unstructured":"Alcolea D, Martinez-Lage P, Sanchez-Juan P, Olazaran J, Antunez C, Izagirre A, Ecay-Torres M, Estanga A, Clerigue M, Guisasola MC, et al. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology. 2015;85:626\u201333.","journal-title":"Neurology."},{"key":"477_CR52","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1093\/brain\/awy159","volume":"141","author":"FK Wiseman","year":"2018","unstructured":"Wiseman FK, Pulford LJ, Barkus C, Liao F, Portelius E, Webb R, Chavez-Gutierrez L, Cleverley K, Noy S, Sheppard O, et al. Trisomy of human chromosome 21 enhances amyloid-beta deposition independently of an extra copy of APP. Brain. 2018;141:2457\u201374.","journal-title":"Brain."},{"key":"477_CR53","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1212\/WNL.0b013e3181b78448","volume":"73","author":"JC Lambert","year":"2009","unstructured":"Lambert JC, Schraen-Maschke S, Richard F, Fievet N, Rouaud O, Berr C, Dartigues JF, Tzourio C, Alperovitch A, Buee L, Amouyel P. Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. Neurology. 2009;73:847\u201353.","journal-title":"Neurology."},{"key":"477_CR54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.dadm.2017.07.004","volume":"8","author":"N Fandos","year":"2017","unstructured":"Fandos N, Perez-Grijalba V, Pesini P, Olmos S, Bossa M, Villemagne VL, Doecke J, Fowler C, Masters CL, Sarasa M, Group AR. Plasma amyloid beta 42\/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst). 2017;8:179\u201387.","journal-title":"Alzheimers Dement (Amst)"},{"key":"477_CR55","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, Fowler C, Li QX, Martins R, Rowe C, et al. High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease. Nature. 2018;554:249\u201354.","journal-title":"Nature."},{"key":"477_CR56","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13:841\u20139.","journal-title":"Alzheimers Dement"},{"key":"477_CR57","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, Song L, Hanlon D, Tan Hehir CA, Baker D, et al. Plasma beta-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep. 2016;6:26801.","journal-title":"Sci Rep"},{"key":"477_CR58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40120-017-0073-9","volume":"6","author":"K Blennow","year":"2017","unstructured":"Blennow K. A review of fluid biomarkers for Alzheimer\u2019s disease: moving from CSF to blood. Neurol Ther. 2017;6:15\u201324.","journal-title":"Neurol Ther"},{"key":"477_CR59","doi-asserted-by":"crossref","unstructured":"Buss L, Fisher E, Hardy J, Nizetic D, Groet J, Pulford L, Strydom A. Intracerebral haemorrhage in Down syndrome: protected or predisposed? F1000Res. 2016;5:876.","DOI":"10.12688\/f1000research.7819.1"},{"key":"477_CR60","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.neulet.2008.12.030","volume":"451","author":"EL Jones","year":"2009","unstructured":"Jones EL, Hanney M, Francis PT, Ballard CG. Amyloid beta concentrations in older people with Down syndrome and dementia. Neurosci Lett. 2009;451:162\u20134.","journal-title":"Neurosci Lett"},{"key":"477_CR61","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/gps.2321","volume":"25","author":"VP Prasher","year":"2010","unstructured":"Prasher VP, Sajith SG, Mehta P, Zigman WB, Schupf N. Plasma beta-amyloid and duration of Alzheimer\u2019s disease in adults with Down syndrome. Int J Geriatr Psychiatry. 2010;25:202\u20137.","journal-title":"Int J Geriatr Psychiatry"},{"key":"477_CR62","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/WAD.0b013e3181aba61e","volume":"23","author":"Y Matsuoka","year":"2009","unstructured":"Matsuoka Y, Andrews HF, Becker AG, Gray AJ, Mehta PD, Sano MC, Dalton AJ, Aisen PS. The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome. Alzheimer Dis Assoc Disord. 2009;23:315\u20138.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"477_CR63","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/archneur.64.7.1007","volume":"64","author":"N Schupf","year":"2007","unstructured":"Schupf N, Patel B, Pang D, Zigman WB, Silverman W, Mehta PD, Mayeux R. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol. 2007;64:1007\u201313.","journal-title":"Arch Neurol"},{"key":"477_CR64","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3389\/fnbeh.2015.00239","volume":"9","author":"MS Rafii","year":"2015","unstructured":"Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, Aisen PS, Rissman RA. The Down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer\u2019s disease biomarkers in Down syndrome. Front Behav Neurosci. 2015;9:239.","journal-title":"Front Behav Neurosci"},{"key":"477_CR65","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.neurobiolaging.2003.10.004","volume":"25","author":"E Matsubara","year":"2004","unstructured":"Matsubara E, Sekijima Y, Tokuda T, Urakami K, Amari M, Shizuka-Ikeda M, Tomidokoro Y, Ikeda M, Kawarabayashi T, Harigaya Y, et al. Soluble Abeta homeostasis in AD and DS: impairment of anti-amyloidogenic protection by lipoproteins. Neurobiol Aging. 2004;25:833\u201341.","journal-title":"Neurobiol Aging"},{"key":"477_CR66","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jalz.2018.08.009","volume":"15","author":"CM Startin","year":"2019","unstructured":"Startin CM, Hamburg S, Hithersay R, Al-Janabi T, Mok KY, Hardy J, LonDownS Strydom A. Cognitive markers of preclinical and prodromal Alzheimer\u2019s disease in Down syndrome. Alzheimers Dement. 2019;15:245\u201357.","journal-title":"Alzheimers Dement"},{"key":"477_CR67","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neulet.2009.04.020","volume":"458","author":"AM Coppus","year":"2009","unstructured":"Coppus AM, Fekkes D, Verhoeven WM, Evenhuis HM, van Duijn CM. Neopterin and the risk of dementia in persons with Down syndrome. Neurosci Lett. 2009;458:60\u20134.","journal-title":"Neurosci Lett"},{"key":"477_CR68","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.neulet.2016.11.023","volume":"636","author":"P Zis","year":"2017","unstructured":"Zis P, Strydom A, Buckley D, Adekitan D, McHugh PC. Cognitive ability in Down syndrome and its relationship to urinary neopterin, a marker of activated cellular immunity. Neurosci Lett. 2017;636:254\u20137.","journal-title":"Neurosci Lett"},{"key":"477_CR69","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3233\/JAD-140783","volume":"43","author":"AD Dekker","year":"2015","unstructured":"Dekker AD, Coppus AM, Vermeiren Y, Aerts T, van Duijn CM, Kremer BP, Naude PJ, Van Dam D, De Deyn PP. Serum MHPG strongly predicts conversion to Alzheimer\u2019s disease in behaviorally characterized subjects with Down syndrome. J Alzheimers Dis. 2015;43:871\u201391.","journal-title":"J Alzheimers Dis"},{"key":"477_CR70","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1365-2826.2011.02118.x","volume":"23","author":"J Landt","year":"2011","unstructured":"Landt J, Ball SL, Holland AJ, Hon J, Owen A, Treppner P, Herbert J. Age-related changes in plasma dehydroepiandrosterone levels in adults with Down\u2019s syndrome and the risk of dementia. J Neuroendocrinol. 2011;23:450\u20135.","journal-title":"J Neuroendocrinol"},{"key":"477_CR71","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3233\/JAD-2012-120073","volume":"31","author":"P Zis","year":"2012","unstructured":"Zis P, Dickinson M, Shende S, Walker Z, Strydom A. Oxidative stress and memory decline in adults with Down syndrome: longitudinal study. J Alzheimers Dis. 2012;31:277\u201383.","journal-title":"J Alzheimers Dis"},{"key":"477_CR72","doi-asserted-by":"publisher","first-page":"e97709","DOI":"10.1371\/journal.pone.0097709","volume":"9","author":"P Zis","year":"2014","unstructured":"Zis P, McHugh P, McQuillin A, Pratico D, Dickinson M, Shende S, Walker Z, Strydom A. Memory decline in Down syndrome and its relationship to iPF2alpha, a urinary marker of oxidative stress. PLoS One. 2014;9:e97709.","journal-title":"PLoS One"},{"key":"477_CR73","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2217\/bmm-2017-0433","volume":"12","author":"NJ Ashton","year":"2018","unstructured":"Ashton NJ, Scholl M, Heurling K, Gkanatsiou E, Portelius E, Hoglund K, Brinkmalm G, Hye A, Blennow K, Zetterberg H. Update on biomarkers for amyloid pathology in Alzheimer\u2019s disease. Biomark Med. 2018;12:799\u2013812.","journal-title":"Biomark Med"},{"key":"477_CR74","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jalz.2016.08.012","volume":"13","author":"ED Hamlett","year":"2017","unstructured":"Hamlett ED, Goetzl EJ, Ledreux A, Vasilevko V, Boger HA, LaRosa A, Clark D, Carroll SL, Carmona-Iragui M, Fortea J, et al. Neuronal exosomes reveal Alzheimer\u2019s disease biomarkers in Down syndrome. Alzheimers Dement. 2017;13:541\u20139.","journal-title":"Alzheimers Dement"},{"key":"477_CR75","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/j.neurobiolaging.2011.08.007","volume":"33","author":"AM Coppus","year":"2012","unstructured":"Coppus AM, Schuur M, Vergeer J, Janssens AC, Oostra BA, Verbeek MM, van Duijn CM. Plasma beta amyloid and the risk of Alzheimer\u2019s disease in Down syndrome. Neurobiol Aging. 2012;33:1988\u201394.","journal-title":"Neurobiol Aging"},{"key":"477_CR76","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1212\/WNL.0b013e3181fb448b","volume":"75","author":"N Schupf","year":"2010","unstructured":"Schupf N, Zigman WB, Tang MX, Pang D, Mayeux R, Mehta P, Silverman W. Change in plasma AB peptides and onset of dementia in adults with Down syndrome. Neurology. 2010;75:1639\u201344.","journal-title":"Neurology."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0477-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-019-0477-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0477-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T17:51:43Z","timestamp":1606931503000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-019-0477-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,21]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["477"],"URL":"https:\/\/doi.org\/10.1186\/s13195-019-0477-0","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,21]]},"assertion":[{"value":"28 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"For adults with DS, ethical approval was obtained from the North West Wales Research Ethics Committee (13\/WA\/0194). Where individuals had capacity to consent for themselves we obtained written informed consent. Where individuals did not have capacity to consent a consultee was asked to approve the individual\u2019s inclusion based on their knowledge of the individual and his\/her wishes, in accordance with the UK Mental Capacity Act 2005.For adults with sAD and controls, ethical approval was obtained from the regional ethics committee. Plasma and CSF samples were routinely collected in all subjects undergoing a diagnostic work-up for suspected neurodegenerative diseases, with informed written consent obtained for their use in research from patients or their representatives.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HZ has served at scientific advisory boards for Eli Lilly, Roche Diagnostics and Wave, has received travel support from Teva, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"26"}}